Director, Head of Research, Smartkarma

Pranav Rao

Director, Head of Research

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
<li>Welcome to Curator’s Cut — a roundup of standout themes from the 1,900+ insights published on Smartkarma over the past month. </li>
<li>In this cut, we spotlight fresh additions to our 2026 high conviction list, review the strong pipeline of China healthcare IPOs, and assess sentiment after the strong year-end metals rally.</li>
<li>Want to dig deeper? Comment or message with the themes you’d like to see highlighted next.</li>
</ul>


Welcome to Curator’s Cut — a roundup of standout themes from the 1,900+ insights published on Smartkarma over the past month. 
In this cut, we spotlight fresh additions to our 2026 high conviction list, review the strong pipeline of China healthcare IPOs, and assess sentiment after the strong year-end metals rally.
Want to dig deeper? Comment or message with the themes you’d like to see highlighted next.


Curator's Cut: Expanding 2026 Top Picks, China Healthcare IPO Bonanza & The Metals March

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

SBI Shinsei Bank / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, HK IPOs continue to be launched into the year end.</li>
<li>On the placements front, there are a number of lockup expiries coming up over the next few weeks.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, HK IPOs continue to be launched into the year end.
On the placements front, there are a number of lockup expiries coming up over the next few weeks.


ECM Weekly (22 December 2025) - SBI Shinsei, ICICI AMC, Insilico, Forest Cabin Sanhua, IFBH, CaoCao

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Forest Cabin Cosmetics / Equity Capital Markets

<ul>
<li>FOREST CABIN holds a leading position in camellia oil segmentation, with mid-to-high end positioning and high gross profit margin. But high operating cost will put pressure on net profit margin.</li>
<li>Considering the risk of recession/depression, consumption downgrade and reducing non-rigid spending will be the main theme in short term. 50% YoY revenue growth in 2024 is likely to be unsustainable.</li>
<li>Valuation of FOREST CABIN could be lower than peers. Stock price performance would highly depend on market sentiment, company growth trend, and visibility of profitability at the time of listing.</li>
</ul>


FOREST CABIN holds a leading position in camellia oil segmentation, with mid-to-high end positioning and high gross profit margin. But high operating cost will put pressure on net profit margin.
Considering the risk of recession/depression, consumption downgrade and reducing non-rigid spending will be the main theme in short term. 50% YoY revenue growth in 2024 is likely to be unsustainable.
Valuation of FOREST CABIN could be lower than peers. Stock price performance would highly depend on market sentiment, company growth trend, and visibility of profitability at the time of listing.


Pre-IPO Shanghai Forest Cabin Biological-Tech - The Business Model and the Concerns Behind

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, there was a lack of fireworks from last week's listing. This week might have some better luck.</li>
<li>On the placements front, there was no dearth of deals with raisings across the region.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, there was a lack of fireworks from last week's listing. This week might have some better luck.
On the placements front, there was no dearth of deals with raisings across the region.


ECM Weekly (25 August 2025)- Hansoh, Daiichi, IFAST, Guzman, Vikram, Shuandeng, Jiaxin, Forest, Aux

APAC IPOs & Placements, Aequitas Research

Hong Jie Seow

APAC IPOs & Placements

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-forest-cabin-biological-tech-co-ltd" target="_blank" data-smartkarma-citation="entities:45249:1" rel="noopener">Shanghai Forest Cabin Biological-Tech (SFCBT HK)</a>  is looking to raise at least US$100m in its upcoming Hong Kong IPO.</li>
<li>SFC is the leader among China’s premium domestic skincare brands. In 2024, SFC was ranked first among all premium domestic skincare brands in China by retail sales.</li>
<li>In this note, we look at the company’s past performance.</li>
</ul>



Shanghai Forest Cabin Biological-Tech (SFCBT HK)  is looking to raise at least US$100m in its upcoming Hong Kong IPO.
SFC is the leader among China’s premium domestic skincare brands. In 2024, SFC was ranked first among all premium domestic skincare brands in China by retail sales.
In this note, we look at the company’s past performance.


Shanghai Forest Cabin Biological Tech. Pre-IPO: A Play on Aging Population But With A Few Wrinkles

China

Forest Cabin is a premium domestic skincare brand in China, specializing in anti-wrinkle and firming skincare products. The company offers a comprehensive range of skincare solutions, including its flagship Camellia Essence Oil, face creams, toners, and facial masks. Founded in 2003, its headquarters are located in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Forest Cabin Cosmetics (2657 HK)

Curator's Cut: Expanding 2026 Top Picks, China Healthcare IPO Bonanza & The Metals March

In the first issue of Curator's Cut in 2026, we review more high conviction ideas, the pipeline of China healthcare IPOs, and sentiment around...

Pranav Rao

ECM Weekly (22 December 2025) - SBI Shinsei, ICICI AMC, Insilico, Forest Cabin Sanhua, IFBH, CaoCao

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pre-IPO Shanghai Forest Cabin Biological-Tech - The Business Model and the Concerns Behind

Forest Cabin's leading position in camellia oil market could be challenged by high operating costs and potential economic downturn, impacting...

Xinyao (Criss) Wang

ECM Weekly (25 August 2025)- Hansoh, Daiichi, IFAST, Guzman, Vikram, Shuandeng, Jiaxin, Forest, Aux

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Shanghai Forest Cabin Biological Tech. Pre-IPO: A Play on Aging Population But With A Few Wrinkles

Shanghai Forest Cabin Biological-Tech aims to raise over US$100m in Hong Kong IPO, leading China's premium skincare market with top retail sales...

Hong Jie Seow

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Curator's Cut: Expanding 2026 Top Picks, China Healthcare IPO Bonanza & The Metals March

​In the first issue of Curator's Cut in 2026, we review more high conviction ideas, the pipeline of China healthcare IPOs, and sentiment around...

Pranav Rao

ECM Weekly (22 December 2025) - SBI Shinsei, ICICI AMC, Insilico, Forest Cabin Sanhua, IFBH, CaoCao

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pre-IPO Shanghai Forest Cabin Biological-Tech - The Business Model and the Concerns Behind

​Forest Cabin's leading position in camellia oil market could be challenged by high operating costs and potential economic downturn, impacting...

Xinyao (Criss) Wang

ECM Weekly (25 August 2025)- Hansoh, Daiichi, IFAST, Guzman, Vikram, Shuandeng, Jiaxin, Forest, Aux

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Shanghai Forest Cabin Biological Tech. Pre-IPO: A Play on Aging Population But With A Few Wrinkles

​Shanghai Forest Cabin Biological-Tech aims to raise over US$100m in Hong Kong IPO, leading China's premium skincare market with top retail sales...

Hong Jie Seow

In the first issue of Curator's Cut in 2026, we review more high conviction ideas, the pipeline of China healthcare IPOs, and sentiment around...

Forest Cabin's leading position in camellia oil market could be challenged by high operating costs and potential economic downturn, impacting...

Shanghai Forest Cabin Biological-Tech aims to raise over US$100m in Hong Kong IPO, leading China's premium skincare market with top retail sales...